BRAF Mutations in NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
BRAF Mutations in NSCLC Market Outlook
Thelansis’s “BRAF Mutations in NSCLC
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential BRAF Mutations in NSCLC treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
BRAF
Mutations in NSCLC Overview
BRAF
mutations are rare in non-small cell lung cancer (NSCLC), occurring in about
1-5% of cases. However, they are most common in lung adenocarcinoma, a specific
type of NSCLC. The most common BRAF mutation is V600E, found in more than 50%
of cases with a BRAF mutation. V600E BRAF mutation is also the most common BRAF
mutation in melanoma, a type of skin cancer. In melanoma, V600E BRAF mutation
is associated with a significant dependency on MEK activity. This means cells
with V600E BRAF mutation depend highly on the MEK protein to grow and survive.
This provides a rational therapeutic strategy for V600E BRAF-mutant melanoma,
as drugs that block MEK activity can effectively kill these cells. In lung
adenocarcinoma, the frequency of V600E BRAF mutation is lower, at 1.5-2.8%.
However, growing evidence shows that BRAF inhibitors, such as vemurafenib and
dabrafenib, can effectively treat lung adenocarcinoma with V600E BRAF mutation.
BRAF mutations are rare in NSCLC but are most common in lung adenocarcinoma. The
V600E BRAF mutation is the most common in both NSCLC and melanoma. Promising
targeted therapies are available for patients with V600E BRAF-mutant lung
adenocarcinoma and melanoma.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment